Specialty medications and injectables are changing how we treat chronic diseases-but they’re also breaking the bank. These drugs, used for conditions like cancer, multiple sclerosis, and rheumatoid arthritis, make up just 2% of all prescriptions but account for half of all pharmacy spending. In 2023, the U.S. spent over $200 billion on these drugs alone, and that number is projected to hit $350 billion by 2027. For employers, the average cost per employee is $34.50 per month. That’s not a small line item-it’s a financial pressure point that’s growing faster than wages or inflation.

Start with Formulary Management

One of the most effective ways to cut costs is by tightening your pharmacy benefit manager’s (PBM) formulary. This means deciding which drugs are covered and under what conditions. Not all specialty drugs are created equal. Some have cheaper, equally effective alternatives. Formulary management uses tools like prior authorization, step therapy, and quantity limits to steer patients toward the best value.

For example, Excellus BlueCross BlueShield found that using a structured prior authorization process for GLP-1 weight loss drugs saved $13.64 per member per month compared to national PBM plans. That’s over $160 per year per person. The key? Clinical oversight. When pharmacists and clinicians review each request-not just automated systems-you prevent unnecessary prescriptions without blocking access. Employers who implemented this saw 87% satisfaction from members who still got the drugs they needed, just with better oversight.

Use Narrow Pharmacy Networks

Instead of letting patients use any specialty pharmacy, limit them to a small group of high-performing providers. This isn’t about restriction-it’s about leverage. When you contract with fewer pharmacies, you get better pricing. CarelonRx found that narrow networks reduce costs by 10-15% on average. Why? These pharmacies agree to lower rates because they get more volume. They also tend to offer better clinical support: home delivery, nurse coaching, refill reminders.

Children’s Hospital Association tracked a network of 10 preferred specialty pharmacies that saved $1.3 billion over three years. That’s a 10% reduction on $13 billion in gross spending. The catch? You need to communicate clearly. Some patients resisted switching pharmacies at first. About 22% of employers saw a spike in call center volume during the transition. But after six months, satisfaction rose because patients got better service. The savings were real-and so were the outcomes.

Switch to Biosimilars When Possible

Biosimilars are the generic version of biologic drugs. They’re not copies-they’re highly similar, FDA-approved versions that work the same way. The difference? Price. Biosimilars cost about 50% less than their brand-name counterparts. Quantum Health estimates that if biosimilars were adopted widely, the U.S. could save $180 billion over five years.

Yet adoption is still low. Only 30% of eligible patients use them. Why? Prescribers are hesitant. Patients don’t know the difference. Insurance doesn’t always make it easy. But hospitals that pushed biosimilar transitions saw 20-30% cost drops with no loss in effectiveness. The solution? Education. Provide doctors with data. Show them real-world outcomes. Let pharmacists lead the conversation. Make biosimilars the default unless there’s a clear clinical reason not to. The FDA has approved 42 biosimilars as of 2023. Most are ready to use now.

Move Infusions Out of Hospitals

Many injectables require infusion-slow delivery through an IV. Hospitals charge $500-$1,200 per session. A doctor’s office? $100-$200. Home infusion? Often less than $50. Quantum Health studied 220 specialty drugs and found that 91% of patients who received infusions in hospitals could have safely received them elsewhere. When they moved those patients, costs dropped by 48%.

This isn’t theoretical. Prime Therapeutics saw 40-50% savings when patients switched from hospital outpatient departments to physician offices or home care. The trick? You need to coordinate care. Make sure the new site has trained staff, proper equipment, and emergency protocols. Offer transportation help if needed. Train patients on home administration if they’re eligible. For drugs like Enbrel or Humira, home infusion is safe, effective, and far cheaper. And patients prefer it-87% report higher satisfaction when they can receive treatment in their own home.

Maximize Rebates and Financial Assistance

Manufacturer rebates are hidden savings that most plans leave on the table. When a drug company offers a rebate to your PBM, it’s often not passed on to the plan sponsor. CarelonRx found that optimizing rebate structures can reduce net costs by 5-8% annually. That’s not a small win-it’s a game-changer for large employers.

Also, use copay maximizer programs. These let patients use manufacturer coupons without counting toward their deductible. That means they pay $0 out-of-pocket, and the plan pays less. For example, a patient on a $1,500/month drug might have a $500 copay. A maximizer program lets them use a $1,000 coupon, so they pay nothing. The manufacturer covers the rest. The plan pays less than if the patient paid the full copay. This reduces financial burden on patients and lowers employer spend.

Combine Strategies for Maximum Impact

No single tactic does it all. Formulary management reduces inappropriate use. Narrow networks cut prices. Biosimilars slash costs. Treatment setting changes eliminate waste. Rebates and copay maximizers stretch every dollar further. Experts agree: the most successful programs use at least three of these together.

Employers using four or more strategies cut specialty drug growth from 10-12% per year to just 5-7%. That’s a difference of $45-60 billion industry-wide by 2027. It’s not magic. It’s strategy. And it’s working right now.

What’s Holding You Back?

Some worry about access. Others fear backlash from patients or providers. But the data shows the opposite: when done right, these strategies improve care while lowering costs. Patients get better support. Clinicians get clearer guidelines. Employers get control over runaway spending.

Start small. Pick one area. Maybe it’s switching your GLP-1 drugs to a narrow network. Or launching a biosimilar education campaign for your oncology patients. Track the results. Measure savings. Ask patients for feedback. Then expand.

The cost of doing nothing is higher than the cost of change. Specialty drugs aren’t going away. But how you manage them? That’s still in your hands.